Literature DB >> 16566870

Epilepsy and chromosomal rearrangements in Smith-Magenis Syndrome [del(17)(p11.2p11.2)].

Alica M Goldman1, Lorraine Potocki, Katherina Walz, Jennifer K Lynch, Daniel G Glaze, James R Lupski, Jeffrey L Noebels.   

Abstract

Smith-Magenis syndrome is a multiple congenital anomalies/mental retardation syndrome associated with a heterozygous deletion of chromosome 17p11.2. Seizures have not been formally studied in this population. Our objectives were to estimate the prevalence of seizures and electroencephalographic (EEG) epileptiform abnormalities in patients with Smith-Magenis syndrome with defined chromosomal rearrangements and to describe the spectrum of abnormal EEG patterns. Prolonged video-EEGs were obtained in 60 patients. Eighteen percent of patients reported a seizure history; however, abnormal EEGs were identified in 31 of the 60 subjects and 27 of 31 were epileptiform. Generalized epileptiform patterns were the most common (73%). Most patients with either small or large deletions had an abnormal EEG (83%; 75%) in contrast to those with a common deletion (49%). Our results indicate that epileptiform EEG abnormalities are frequent in patients with Smith-Magenis syndrome. Considering that close to one third of individuals with Smith-Magenis syndrome with epileptiform abnormalities also had a history of clinical seizures, cortical hyperexcitability and epilepsy should be considered an important component of the Smith-Magenis syndrome clinical phenotype.

Entities:  

Mesh:

Year:  2006        PMID: 16566870     DOI: 10.1177/08830738060210021201

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  12 in total

Review 1.  CHD associated with syndromic diagnoses: peri-operative risk factors and early outcomes.

Authors:  Benjamin J Landis; David S Cooper; Robert B Hinton
Journal:  Cardiol Young       Date:  2015-09-08       Impact factor: 1.093

Review 2.  Neurodevelopmental Disorders Associated with Abnormal Gene Dosage: Smith-Magenis and Potocki-Lupski Syndromes.

Authors:  Juanita Neira-Fresneda; Lorraine Potocki
Journal:  J Pediatr Genet       Date:  2015-09-28

Review 3.  Epilepsy and Autism.

Authors:  Ashura W Buckley; Gregory L Holmes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

4.  Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior.

Authors:  Paulina Carmona-Mora; Katherina Walz
Journal:  Curr Genomics       Date:  2010-12       Impact factor: 2.236

5.  Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype.

Authors:  Lorraine Potocki; Weimin Bi; Diane Treadwell-Deering; Claudia M B Carvalho; Anna Eifert; Ellen M Friedman; Daniel Glaze; Kevin Krull; Jennifer A Lee; Richard Alan Lewis; Roberto Mendoza-Londono; Patricia Robbins-Furman; Chad Shaw; Xin Shi; George Weissenberger; Marjorie Withers; Svetlana A Yatsenko; Elaine H Zackai; Pawel Stankiewicz; James R Lupski
Journal:  Am J Hum Genet       Date:  2007-02-26       Impact factor: 11.025

6.  Functional and cellular characterization of human Retinoic Acid Induced 1 (RAI1) mutations associated with Smith-Magenis Syndrome.

Authors:  Paulina Carmona-Mora; Carolina A Encina; Cesar P Canales; Lei Cao; Jessica Molina; Pamela Kairath; Juan I Young; Katherina Walz
Journal:  BMC Mol Biol       Date:  2010-08-25       Impact factor: 2.946

7.  Rai1 Haploinsufficiency Is Associated with Social Abnormalities in Mice.

Authors:  Nalini R Rao; Clemer Abad; Irene C Perez; Anand K Srivastava; Juan I Young; Katherina Walz
Journal:  Biology (Basel)       Date:  2017-04-27

8.  A cross-syndrome cohort comparison of sleep disturbance in children with Smith-Magenis syndrome, Angelman syndrome, autism spectrum disorder and tuberous sclerosis complex.

Authors:  J Trickett; M Heald; C Oliver; C Richards
Journal:  J Neurodev Disord       Date:  2018-03-01       Impact factor: 4.025

9.  Mouse models of genomic syndromes as tools for understanding the basis of complex traits: an example with the smith-magenis and the potocki-lupski syndromes.

Authors:  P Carmona-Mora; J Molina; C A Encina; K Walz
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

10.  Behavioral disturbance and treatment strategies in Smith-Magenis syndrome.

Authors:  Alice Poisson; Alain Nicolas; Pierre Cochat; Damien Sanlaville; Caroline Rigard; Hélène de Leersnyder; Patricia Franco; Vincent Des Portes; Patrick Edery; Caroline Demily
Journal:  Orphanet J Rare Dis       Date:  2015-09-04       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.